Viatris is rebounding after retracing to the $16 support level. The stock remains in a bullish trend, continuing to form higher highs and higher lows while trading above well-aligned 20-day and 50-day moving averages.
Viatris, Inc. is a global healthcare company engaged in the development and distribution of pharmaceutical products and healthcare solutions. The company offers medicines and treatments across several therapeutic areas, including cardiovascular care, oncology, dermatology, eye care, gastroenterology, immunology, and women’s healthcare.
The company operates through four major segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment primarily covers North America and Europe, while the Greater China segment includes mainland China, Taiwan, and Hong Kong. The JANZ segment encompasses Japan, Australia, and New Zealand, and the Emerging Markets segment serves developing economies across Asia, the Middle East, Africa, Eastern Europe, and South and Central America.
VTRS has grown revenue consistently over the last three quarters and delivered EPS growth in two of the last three quarters. Operating and net margins stand at 10% and 5%, respectively. The company’s Current Ratio is 1.5x, while Debt-to-Equity is 1.0x. However, profitability metrics remain under pressure, with ROE and ROIC at -1.96% and -1.04%, respectively.
Viatris, Inc. is a global healthcare company engaged in the development and distribution of pharmaceutical products and healthcare solutions. The company offers medicines and treatments across several therapeutic areas, including cardiovascular care, oncology, dermatology, eye care, gastroenterology, immunology, and women’s healthcare.
The company operates through four major segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment primarily covers North America and Europe, while the Greater China segment includes mainland China, Taiwan, and Hong Kong. The JANZ segment encompasses Japan, Australia, and New Zealand, and the Emerging Markets segment serves developing economies across Asia, the Middle East, Africa, Eastern Europe, and South and Central America.
VTRS has grown revenue consistently over the last three quarters and delivered EPS growth in two of the last three quarters. Operating and net margins stand at 10% and 5%, respectively. The company’s Current Ratio is 1.5x, while Debt-to-Equity is 1.0x. However, profitability metrics remain under pressure, with ROE and ROIC at -1.96% and -1.04%, respectively.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.